RU2758008C2 - Анти-il-5 антитела - Google Patents

Анти-il-5 антитела Download PDF

Info

Publication number
RU2758008C2
RU2758008C2 RU2019123112A RU2019123112A RU2758008C2 RU 2758008 C2 RU2758008 C2 RU 2758008C2 RU 2019123112 A RU2019123112 A RU 2019123112A RU 2019123112 A RU2019123112 A RU 2019123112A RU 2758008 C2 RU2758008 C2 RU 2758008C2
Authority
RU
Russia
Prior art keywords
amino acid
acid sequence
seq
light chain
ser
Prior art date
Application number
RU2019123112A
Other languages
English (en)
Russian (ru)
Other versions
RU2019123112A3 (cg-RX-API-DMAC7.html
RU2019123112A (ru
Inventor
Марк Теренс Лиддамент
Энтони Дойл
Адам Кларк
Девид Хосе Саймон Лейн
Бриджит Энн Кукси
Original Assignee
Сефалон, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сефалон, Инк. filed Critical Сефалон, Инк.
Publication of RU2019123112A publication Critical patent/RU2019123112A/ru
Publication of RU2019123112A3 publication Critical patent/RU2019123112A3/ru
Application granted granted Critical
Publication of RU2758008C2 publication Critical patent/RU2758008C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2019123112A 2016-12-23 2017-12-20 Анти-il-5 антитела RU2758008C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662438502P 2016-12-23 2016-12-23
US62/438,502 2016-12-23
PCT/US2017/067475 WO2018119016A1 (en) 2016-12-23 2017-12-20 Anti-il-5 antibodies

Publications (3)

Publication Number Publication Date
RU2019123112A RU2019123112A (ru) 2021-01-26
RU2019123112A3 RU2019123112A3 (cg-RX-API-DMAC7.html) 2021-04-05
RU2758008C2 true RU2758008C2 (ru) 2021-10-25

Family

ID=60972458

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019123112A RU2758008C2 (ru) 2016-12-23 2017-12-20 Анти-il-5 антитела

Country Status (20)

Country Link
US (2) US11111292B2 (cg-RX-API-DMAC7.html)
EP (1) EP3559030B1 (cg-RX-API-DMAC7.html)
JP (1) JP7060906B2 (cg-RX-API-DMAC7.html)
KR (1) KR102651290B1 (cg-RX-API-DMAC7.html)
CN (1) CN110267986B (cg-RX-API-DMAC7.html)
AR (1) AR110564A1 (cg-RX-API-DMAC7.html)
AU (1) AU2017379853B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019012929A2 (cg-RX-API-DMAC7.html)
CA (1) CA3048186A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019001730A1 (cg-RX-API-DMAC7.html)
EA (1) EA201991552A1 (cg-RX-API-DMAC7.html)
ES (1) ES2984636T3 (cg-RX-API-DMAC7.html)
IL (1) IL267271B2 (cg-RX-API-DMAC7.html)
MX (1) MX2019007642A (cg-RX-API-DMAC7.html)
NZ (1) NZ754606A (cg-RX-API-DMAC7.html)
PE (1) PE20191662A1 (cg-RX-API-DMAC7.html)
PH (1) PH12019501452A1 (cg-RX-API-DMAC7.html)
RU (1) RU2758008C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018119016A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201904097B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201991552A1 (ru) * 2016-12-23 2020-01-09 Сефалон, Инк. Анти-il-5 антитела
SMT202600240T1 (it) 2017-05-26 2026-07-16 Glaxosmithkline Ip Dev Ltd Composizioni biofarmaceutiche e metodi correlati
CN113366016B (zh) * 2018-12-12 2022-12-16 上海开拓者生物医药有限公司 抗人白细胞介素5(il-5)单克隆抗体及其应用
JP7641908B2 (ja) 2019-03-29 2025-03-07 ジエンス ヘンルイ メデイシンカンパニー リミテッド Ｉｌ－５に対する抗体を含有する医薬組成物及びその使用
CN112745389B (zh) * 2019-10-29 2022-11-25 瑞阳(苏州)生物科技有限公司 结合人il-5的单克隆抗体及其应用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996021000A2 (en) * 1994-12-23 1996-07-11 Smithkline Beecham Corporation Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders
WO2003085089A2 (en) * 2002-03-29 2003-10-16 Schering Corporation Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US6056957A (en) * 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
US5683892A (en) * 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
ES3053874T3 (en) 2015-08-24 2026-01-27 Glaxosmithkline Ip No 2 Ltd Biopharmaceutical compositions
EP3365369A1 (en) * 2015-10-23 2018-08-29 Pfizer Inc Anti-il-2 antibodies and compositions and uses thereof
EA201991552A1 (ru) * 2016-12-23 2020-01-09 Сефалон, Инк. Анти-il-5 антитела

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996021000A2 (en) * 1994-12-23 1996-07-11 Smithkline Beecham Corporation Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders
WO2003085089A2 (en) * 2002-03-29 2003-10-16 Schering Corporation Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
STROHL W.R., Optimization of Fc-mediated effector functions of monoclonal antibodies, Current Opinion in Biotechnology, 2009, Volume 20, Issue 6, pp.685-691. *
STROHL W.R., Optimization of Fc-mediated effector functions of monoclonal antibodies, Current Opinion in Biotechnology, 2009, Volume 20, Issue 6, pp.685-691. ЧУЧАЛИН А.Г., Новые перспективы в терапии бронхиальной астмы, Пульмонология, 2011, Номер 4, с.5-12. КОЛХИР П.В., СМОЛКИН Ю.С., Клинические фенотипы бронхиальной астмы, Аллергология и иммунология в педиатрии, 2010, Номер 2 (21), с.12-17. *
КОЛХИР П.В., СМОЛКИН Ю.С., Клинические фенотипы бронхиальной астмы, Аллергология и иммунология в педиатрии, 2010, Номер 2 (21), с.12-17. *
ЧУЧАЛИН А.Г., Новые перспективы в терапии бронхиальной астмы, Пульмонология, 2011, Номер 4, с.5-12. *

Also Published As

Publication number Publication date
US20210355205A1 (en) 2021-11-18
EP3559030A1 (en) 2019-10-30
MX2019007642A (es) 2019-09-09
ZA201904097B (en) 2023-12-20
WO2018119016A1 (en) 2018-06-28
PE20191662A1 (es) 2019-11-11
EP3559030B1 (en) 2024-04-03
IL267271B2 (en) 2025-10-01
JP2020513761A (ja) 2020-05-21
AR110564A1 (es) 2019-04-10
CN110267986B (zh) 2023-05-09
JP7060906B2 (ja) 2022-04-27
AU2017379853A1 (en) 2019-07-04
ES2984636T3 (es) 2024-10-30
IL267271A (en) 2019-08-29
US20180186873A1 (en) 2018-07-05
RU2019123112A3 (cg-RX-API-DMAC7.html) 2021-04-05
RU2019123112A (ru) 2021-01-26
US12577298B2 (en) 2026-03-17
NZ754606A (en) 2023-06-30
EP3559030C0 (en) 2024-04-03
US11111292B2 (en) 2021-09-07
KR102651290B1 (ko) 2024-03-25
PH12019501452A1 (en) 2020-06-15
EA201991552A1 (ru) 2020-01-09
AU2017379853B2 (en) 2025-02-06
CN110267986A (zh) 2019-09-20
KR20190126769A (ko) 2019-11-12
BR112019012929A2 (pt) 2019-12-10
CA3048186A1 (en) 2018-06-28
IL267271B1 (en) 2025-06-01
CL2019001730A1 (es) 2019-09-27

Similar Documents

Publication Publication Date Title
US12252536B2 (en) Caninized antibodies
KR102651290B1 (ko) 항-il-5 항체
KR102917630B1 (ko) 인간 Tim-3에 대한 모노클로날 항체
JP2019516362A (ja) 抗ｉｌ−３３抗体、その組成物、方法および使用
CN115697491A (zh) Sars-cov-2抗体及其选择和使用方法
CA2980087A1 (en) Antibodies to canine interleukin-4 receptor alpha
MX2008014804A (es) Anticuerpos de afinidad elevada a receptor de il-6 humano.
US20200148778A1 (en) Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof
CN112969714A (zh) 抗cd40抗体、其抗原结合片段及其医药用途
JP7617012B2 (ja) Ｃ５ａＲを標的とする抗体
US11254736B2 (en) Antibodies comprising a common light chain and uses thereof
AU2021358662A1 (en) CD1a ANTIBODIES AND USES THEREOF
CN121226555A (zh) 抗cMET抗体
CN121226557A (zh) 抗cMET抗体
CN121270705A (zh) 抗cMET抗体
US20250243286A1 (en) Antibodies Targeting ActRIIA and ActRIIB
RU2779128C2 (ru) Антитело к cd40, его антигенсвязывающий фрагмент и его медицинское применение
EA042576B1 (ru) Анти-il-5 антитела
HK40015055B (en) Anti-il-5 antibodies
HK40015055A (en) Anti-il-5 antibodies
HK40051457A (en) Anti-cd40 antibody, antigen binding fragment and pharmaceutical use thereof